TGA Proactively Reviews AI-Powered Digital Scribes: Implications for Medical Device Manufacturers Globally

TGA

 

On 16 October 2026, Australia’s Therapeutic Goods Administration (TGA) published the findings of a proactive regulatory review of digital scribes, including AI-enabled software used by healthcare professionals to document clinical consultations and support clinical workflows.

The review highlights an important emerging regulatory issue: software initially developed for administrative purposes may become subject to medical device regulations as its functionality evolves to include clinical decision support.

Key Findings from the TGA Review

The TGA identified approximately 100 digital scribe suppliers operating in Australia and conducted a focused review of 12 products.

Of these 12 products:

  • 8 products included functionality likely to meet the definition of a medical device.
  • 2 products required further information to determine their regulatory status.
  • 2 products appeared unlikely to qualify as medical devices.

Significantly, none of the 12 suppliers had identified their products as medical devices.

It is important to note that the review focused on regulatory status rather than a detailed assessment of product safety, performance, or conformity.

New TGA guidance clarifies the regulatory boundary

Alongside the review findings, the TGA published dedicated guidance explaining when digital scribes are regulated as medical devices.

The guidance distinguishes between software performing purely administrative functions and software incorporating functionality with a therapeutic purpose.

For example:

  • Generally not medical devices: Software limited to recording consultations, transcribing speech, summarising information already provided by healthcare professionals or preparing administrative clinical documentation.
  • Likely to be medical devices: Software that independently identifies or suggests diagnoses, recommends treatments or investigations, prioritises patients, or generates clinical assessments and recommendations.

Importantly, the TGA clarifies that regulatory status depends on the software’s intended purpose, actual functionality and how it is presented to users, including marketing claims.

Simply including a disclaimer that a product is not intended for diagnosis or treatment does not necessarily exclude it from medical device regulation.

The guidance also highlights that software updates introducing new clinical functionality may change a product’s regulatory status, potentially triggering medical device compliance and registration requirements.

Certain clinical decision support software may qualify for an exemption from ARTG inclusion, subject to specific conditions, although applicable medical device regulatory requirements may still apply.

A proactive regulatory approach with international implications

Of particular interest is the TGA’s proactive approach to identifying potential regulatory gaps in an emerging technology sector.

Rather than relying solely on registration applications or reported safety incidents, the TGA undertook a broader market assessment, engaging directly with suppliers to understand their products and potential regulatory obligations.

The TGA has indicated that the findings will inform targeted, proportionate compliance activities and further industry education.

Although this review focuses on Australia, it may provide valuable early warning for manufacturers operating in other jurisdictions, including the European Union, United Kingdom and United States.

Manufacturers of AI-enabled healthcare software should not assume that an existing classification remains appropriate as software capabilities evolve. Similar products may already fall within medical device regulatory frameworks in other markets, even where they were originally marketed as administrative tools.

MDSS recommends that manufacturers proactively review the intended purpose, functionality, marketing claims and regulatory classification of their software across all markets in which they operate, particularly where new AI-enabled functionality has been introduced.

The TGA’s proactive assessment demonstrates the importance of maintaining regulatory oversight throughout the software lifecycle, rather than treating classification as a one-time exercise.

If your products have been impacted or may be impacted by this guidance and are now considered medical devices, please contact MDSS to discuss how we can support the TGA registration process.

Contact us today to discuss your Australian regulatory needs and ensure your market entry strategy aligns with current TGA expectations.

 

Further reading – TGA publications

  1. Digital scribe review outcomes – 16 October 2026⁠
  2. Digital scribes – Guidance on when digital scribes are regulated as medical devices⁠